GB2106111B
(en)
*
|
1981-09-17 |
1985-11-06 |
Takeda Chemical Industries Ltd |
Macbecin derivatives and their production
|
US4578391A
(en)
*
|
1982-01-20 |
1986-03-25 |
Yamanouchi Pharmaceutical Co., Ltd. |
Oily compositions of antitumor drugs
|
JPS59102398A
(ja)
*
|
1982-12-03 |
1984-06-13 |
Takeda Chem Ind Ltd |
新規抗生物質およびその製造法
|
WO1994008578A2
(en)
*
|
1992-10-14 |
1994-04-28 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
|
US5387584A
(en)
*
|
1993-04-07 |
1995-02-07 |
Pfizer Inc. |
Bicyclic ansamycins
|
EP0706516A1
(en)
*
|
1993-06-29 |
1996-04-17 |
Pfizer Inc. |
Ansamycin derivatives as antioncogene and anticancer agents
|
US5932566A
(en)
*
|
1994-06-16 |
1999-08-03 |
Pfizer Inc. |
Ansamycin derivatives as antioncogene and anticancer agents
|
CA2218523A1
(en)
*
|
1995-05-02 |
1996-11-07 |
William J. Welch |
Inducement of thermotolerance with benzoquinonoid ansamycins
|
ATE460423T1
(de)
|
1997-05-14 |
2010-03-15 |
Sloan Kettering Inst Cancer |
Verfahren und zubereitungen zur zerstörung bestimmter proteine
|
US6852496B1
(en)
|
1997-08-12 |
2005-02-08 |
Oregon Health And Science University |
Methods of screening for agents that promote nerve cell growth
|
US6747055B1
(en)
*
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
AU764603B2
(en)
|
1998-07-17 |
2003-08-21 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Water-soluble drugs and methods for their production
|
AU2167000A
(en)
*
|
1998-12-07 |
2000-06-26 |
Ecosmart Technologies, Inc. |
Cancer treatment composition and method using natural plant essential oils
|
US6174875B1
(en)
*
|
1999-04-01 |
2001-01-16 |
University Of Pittsburgh |
Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
|
US7238682B1
(en)
|
1999-04-09 |
2007-07-03 |
Sloan-Kettering Institute For Cancer Research |
Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases
|
EP1169319A4
(en)
|
1999-04-09 |
2005-02-09 |
Sloan Kettering Institutefor C |
METHODS AND COMPOSITIONS FOR DEGRADING AND / OR INHIBITING TYROSINE KINASES BELONGING TO THE HER FAMILY
|
US6979574B1
(en)
*
|
1999-08-06 |
2005-12-27 |
Institut Fuer Diagnostik Forshung Gmbh |
Process for detecting binding reactions with use of the measurement of the relaxation of the double refraction of magnetic particles
|
US6887853B2
(en)
*
|
2000-06-29 |
2005-05-03 |
The Trustees Of Boston University |
Use of geldanamycin and related compounds for treatment of fibrogenic disorders
|
AU2001292548B2
(en)
|
2000-07-28 |
2005-06-16 |
Sloan-Kettering Institute For Cancer Research |
Methods for treating cell proliferative disorders and viral infections
|
CN1473055A
(zh)
|
2000-11-02 |
2004-02-04 |
˹¡-�����ְ�֢�о��� |
通过使用hsp90抑制剂提高细胞毒剂效力的方法
|
WO2002069900A2
(en)
*
|
2001-03-01 |
2002-09-12 |
Conforma Therapeutics Corp. |
Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
|
PT1373215E
(pt)
*
|
2001-03-30 |
2006-12-29 |
Uni S Of A R By The S D Of H H |
Derivado de geldanamicina e metodo de tratamento de cancro utilizando o mesmo
|
EP1404871A4
(en)
*
|
2001-05-23 |
2006-10-04 |
Sloan Kettering Inst Cancer |
METHOD OF TREATING CANCERS ASSOCIATED WITH LEVELS OF HER-2 STUDENTS
|
US20090197852A9
(en)
*
|
2001-08-06 |
2009-08-06 |
Johnson Robert G Jr |
Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
|
EP1420747A4
(en)
*
|
2001-08-06 |
2010-06-02 |
Kosan Biosciences Inc |
ANSAMYCIN BENZOQUINONE
|
US6872715B2
(en)
*
|
2001-08-06 |
2005-03-29 |
Kosan Biosciences, Inc. |
Benzoquinone ansamycins
|
EP1923061A1
(en)
|
2001-09-24 |
2008-05-21 |
Conforma Therapeutic Corporation |
Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
|
CA2460498A1
(en)
*
|
2001-09-24 |
2003-04-03 |
Conforma Therapeutics Corporation |
Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins
|
WO2003066005A2
(en)
*
|
2002-02-08 |
2003-08-14 |
Conforma Therapeutics Corporation |
Ansamycins having improved pharmacological and biological properties
|
WO2003086381A1
(en)
*
|
2002-04-10 |
2003-10-23 |
Conforma Therapeutics Corporation |
Ansamycin formulations and methods for producing and using same
|
US20060148776A1
(en)
*
|
2003-03-13 |
2006-07-06 |
Conforma Therapeutics Corporation |
Drug formulations having long and medium chain triglycerides
|
US20050054625A1
(en)
*
|
2003-05-30 |
2005-03-10 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
|
US7691838B2
(en)
*
|
2003-05-30 |
2010-04-06 |
Kosan Biosciences Incorporated |
Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
|
US20050020534A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
|
US20050054589A1
(en)
*
|
2003-05-30 |
2005-03-10 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
|
US20050020556A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
|
US20050026893A1
(en)
*
|
2003-05-30 |
2005-02-03 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
|
US20050020557A1
(en)
*
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
|
WO2005009345A2
(en)
*
|
2003-06-13 |
2005-02-03 |
Kosan Biosciences, Inc. |
2-desmethyl ansamycin compounds
|
US6875863B1
(en)
|
2003-11-12 |
2005-04-05 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
US6855705B1
(en)
|
2003-11-12 |
2005-02-15 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
CA2545457A1
(en)
|
2003-11-12 |
2005-06-23 |
Kosan Biosciences, Inc. |
11-o-methylgeldanamycin compounds
|
US6887993B1
(en)
|
2003-11-12 |
2005-05-03 |
Kosan Biosciences, Inc. |
11-O-methylgeldanamycin compounds
|
US20060019941A1
(en)
*
|
2003-12-23 |
2006-01-26 |
Infinity Pharmaceuticals, Inc. |
Analogs of benzoquinone-containing ansamycins and methods of use thereof
|
US7282493B2
(en)
*
|
2003-12-23 |
2007-10-16 |
Infinity Pharmaceuticals, Inc. |
Analogs of benzoquinone-containing ansamycins and methods of use thereof
|
US7491701B2
(en)
*
|
2004-01-27 |
2009-02-17 |
Boys Town National Research Hospital |
Peptides that bind to HSP90 proteins
|
DK1729770T3
(da)
*
|
2004-03-15 |
2010-04-12 |
Sunesis Pharmaceuticals Inc |
SNS-595 og fremgangsmåder til anvendelse deraf
|
WO2005105077A1
(en)
*
|
2004-04-28 |
2005-11-10 |
Massachusetts Eye & Ear Infirmary |
Inflammatory eye disease
|
US20050256097A1
(en)
*
|
2004-05-11 |
2005-11-17 |
Kosan Biosciences, Inc. |
Pharmaceutical solution formulations containing 17-AAG
|
US7259156B2
(en)
|
2004-05-20 |
2007-08-21 |
Kosan Biosciences Incorporated |
Geldanamycin compounds and method of use
|
US20080171687A1
(en)
*
|
2004-09-16 |
2008-07-17 |
Abraxis Bioscience, Inc. |
Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
|
US20060067953A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Conforma Therapeutics Corporation |
Oral pharmaceutical formulations and methods for producing and using same
|
WO2006089207A2
(en)
*
|
2005-02-18 |
2006-08-24 |
Abraxis Bioscience, Inc. |
Drugs with improved hydrophobicity for incorporation in medical devices
|
KR20080004550A
(ko)
*
|
2005-03-30 |
2008-01-09 |
콘포마 세러퓨틱스 코포레이션 |
Hsp90-억제제로서 알키닐 피롤로피리미딘 및 관련유사체
|
CA2603462A1
(en)
*
|
2005-04-07 |
2006-10-09 |
Conforma Therapeutics Corporation |
Phospholipid-based pharmaceutical formulations and methods for producing and using same
|
US8173167B2
(en)
|
2005-04-12 |
2012-05-08 |
Wisconsin Alumni Research Foundation |
Micelle composition of polymer and passenger drug
|
MX2007013499A
(es)
*
|
2005-04-29 |
2008-01-24 |
Kosan Biosciences Inc |
Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag en combinacion con un inhibidor de proteasoma.
|
KR20080000682A
(ko)
*
|
2005-04-29 |
2008-01-02 |
코산 바이오사이언시즈, 인코포레이티드 |
17-aag 또는 17-ag, 또는 이들의 프로드럭을 사용한다발성 골수종의 치료 방법
|
US20080032719A1
(en)
*
|
2005-10-01 |
2008-02-07 |
Outland Research, Llc |
Centralized establishment-based tracking and messaging service
|
US20100279994A1
(en)
*
|
2005-06-21 |
2010-11-04 |
Inifinity Discovery, Inc. |
Ansamycin Formulations and Methods of Use Thereof
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
WO2007035963A2
(en)
*
|
2005-09-23 |
2007-03-29 |
Conforma Therapeutics Corporation |
Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
|
US20090042847A1
(en)
*
|
2005-11-23 |
2009-02-12 |
Kosan Biosciences Incorporated |
17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
|
US7648976B2
(en)
*
|
2005-11-23 |
2010-01-19 |
Bristol-Myers Squibb Company |
17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
|
EP1954265A2
(en)
*
|
2005-12-01 |
2008-08-13 |
Conforma Therapeutics Corporation |
Compositions containing ansamycin
|
US20070167422A1
(en)
*
|
2006-01-18 |
2007-07-19 |
Yu Kwok S |
Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
|
WO2007097839A2
(en)
*
|
2006-02-16 |
2007-08-30 |
Massachusetts Eye And Ear Infirmary |
Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
|
US8124773B2
(en)
|
2006-06-12 |
2012-02-28 |
Sunesis Pharmaceuticals, Inc. |
1,8-naphthyridine compounds for the treatment of cancer
|
CA2659861A1
(en)
*
|
2006-08-02 |
2008-02-07 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
|
PE20081506A1
(es)
*
|
2006-12-12 |
2008-12-09 |
Infinity Discovery Inc |
Formulaciones de ansamicina
|
EP2121957A4
(en)
|
2007-01-26 |
2010-11-10 |
Kosan Biosciences Inc |
MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
|
US8303960B2
(en)
*
|
2007-02-27 |
2012-11-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Radiolabeled affibody molecules
|
NZ580313A
(en)
*
|
2007-04-12 |
2011-11-25 |
Joyant Pharmaceuticals Inc |
Smac mimetic dimers and trimers useful as anti-cancer agents
|
MX2009010808A
(es)
*
|
2007-04-12 |
2009-10-29 |
Infinity Discovery Inc |
Formulaciones de ansamicina de hidroquinona.
|
KR20100057007A
(ko)
*
|
2007-07-09 |
2010-05-28 |
글렌 에스. 권 |
치료제의 마이셀 캡슐화
|
US8551964B2
(en)
|
2007-08-23 |
2013-10-08 |
The Regents Of The University Of Colorado |
Hsp90 inhibitors with modified toxicity
|
EP2200653A2
(en)
*
|
2007-09-10 |
2010-06-30 |
University of Massachusetts |
Mitochondria-targeted anti-tumour agents
|
JP6029808B2
(ja)
*
|
2007-10-22 |
2016-11-24 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
併用療法における(+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の使用方法
|
US7960420B2
(en)
*
|
2007-12-21 |
2011-06-14 |
Joyant Pharmaceuticals, Inc |
Diazonamide analogs with improved solubility
|
CN101220068B
(zh)
*
|
2008-01-18 |
2012-06-13 |
中国医学科学院医药生物技术研究所 |
一组格尔德霉素衍生物及其制备方法
|
US20090258869A1
(en)
*
|
2008-02-08 |
2009-10-15 |
The Regents Of The University Of California |
Methods and compounds for treatment or prevention of substance-related disorders
|
AU2009243056B2
(en)
*
|
2008-04-29 |
2015-05-14 |
Joyant Pharmaceuticals, Inc. |
Indoline anti-cancer agents
|
US8153619B2
(en)
*
|
2008-05-22 |
2012-04-10 |
Joyant Pharmaceuticals, Inc. |
Diazonamide analogs
|
KR20110090925A
(ko)
*
|
2008-10-15 |
2011-08-10 |
인피니티 파마슈티컬스, 인코포레이티드 |
안사마이신 하이드로퀴논 조성물
|
DE102008060549A1
(de)
|
2008-12-04 |
2010-06-10 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
|
WO2011038278A2
(en)
|
2009-09-25 |
2011-03-31 |
Wisconsin Alumni Research Foundation |
Micelle encapsulation of therapeutic agents
|
JPWO2011040421A1
(ja)
|
2009-09-29 |
2013-02-28 |
武田薬品工業株式会社 |
スクリーニング方法
|
CA2789879A1
(en)
|
2009-10-28 |
2011-05-19 |
Joyant Pharmaceuticals, Inc. |
Dimeric smac mimetics
|
CN102603635B
(zh)
*
|
2011-01-21 |
2016-08-03 |
杭州华东医药集团生物工程研究所有限公司 |
格尔德霉素衍生物及其制备方法和用途
|
AU2012245702B2
(en)
|
2011-04-22 |
2016-09-29 |
Joyant Pharmaceuticals, Inc. |
Diazonamide analogs
|
US8945627B2
(en)
|
2011-05-05 |
2015-02-03 |
Wisconsin Alumni Research Foundation |
Micelles for the solubilization of gossypol
|
JP6180420B2
(ja)
|
2011-10-14 |
2017-08-16 |
ノバルティス アーゲー |
増殖性疾患の治療のためのhsp90阻害剤と組み合わせた2−カルボキサミドシクロアミノウレア誘導体
|
WO2013074695A1
(en)
|
2011-11-14 |
2013-05-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Hsp90 inhibitors with modified toxicity
|
WO2013105022A2
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
EP3795694A3
(en)
|
2012-10-02 |
2021-06-23 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Methods relating to dna-sensing pathway related conditions
|
KR20150081344A
(ko)
|
2012-11-07 |
2015-07-13 |
노파르티스 아게 |
조합 요법
|
MY174888A
(en)
|
2013-02-19 |
2020-05-20 |
Novartis Ag |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
|
CN103360312B
(zh)
*
|
2013-07-22 |
2015-06-03 |
山东大学 |
一组格尔德霉素衍生物及其应用
|
CA2928568A1
(en)
|
2013-07-26 |
2015-01-29 |
Update Pharma Inc. |
Combinatorial methods to improve the therapeutic benefit of bisantrene
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
EP3094629B1
(en)
|
2014-01-17 |
2018-08-22 |
Novartis AG |
1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
WO2015107493A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
|
EP3274344B1
(en)
|
2015-03-25 |
2019-04-24 |
Novartis Ag |
Formylated n-heterocyclic derivatives as fgfr4 inhibitors
|
WO2016201378A1
(en)
|
2015-06-12 |
2016-12-15 |
Wisconsin Alumni Research Foundation |
Multi-drug combinations that act as potent radiosensitizers
|
ES2741746T3
(es)
|
2015-06-19 |
2020-02-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
ES2805232T3
(es)
|
2015-06-19 |
2021-02-11 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
ES2849560T3
(es)
|
2016-05-04 |
2021-08-19 |
Genoscience Pharma Sas |
Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas
|
ES2810852T3
(es)
|
2016-06-14 |
2021-03-09 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de shp2
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
US10435389B2
(en)
|
2017-09-11 |
2019-10-08 |
Krouzon Pharmaccuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
SG11202100645XA
(en)
|
2018-07-25 |
2021-02-25 |
Advanced Accelerator Applications Sa |
Stable, concentrated radionuclide complex solutions
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
MX2021003158A
(es)
|
2018-09-18 |
2021-07-16 |
Nikang Therapeutics Inc |
Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2.
|
WO2020068873A1
(en)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
EP3856726A1
(en)
|
2018-09-25 |
2021-08-04 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
CN112867512A
(zh)
|
2018-09-25 |
2021-05-28 |
意大利国际先进加速器应用有限公司 |
联合疗法
|
IL305106A
(en)
|
2018-09-29 |
2023-10-01 |
Novartis Ag |
A process for producing a compound to inhibit the activity of SHP2
|
CA3123511A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
EA202192019A1
(ru)
|
2019-02-15 |
2021-11-02 |
Новартис Аг |
Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
|
JP7488826B2
(ja)
|
2019-02-15 |
2024-05-22 |
ノバルティス アーゲー |
置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
KR20220047810A
(ko)
|
2019-08-15 |
2022-04-19 |
블랙 다이아몬드 테라퓨틱스, 인코포레이티드 |
알키닐 퀴나졸린 화합물
|
WO2021123996A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
JP2023531676A
(ja)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
CA3202355A1
(en)
|
2020-12-22 |
2022-06-30 |
Jiping Fu |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
WO2022152821A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
EP4323349A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
EP4323350A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
TW202317589A
(zh)
|
2021-07-14 |
2023-05-01 |
美商尼坎醫療公司 |
作為kras抑制劑的伸烷基衍生物
|
WO2023192801A1
(en)
|
2022-03-28 |
2023-10-05 |
Nikang Therapeutics, Inc. |
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2024102849A1
(en)
|
2022-11-11 |
2024-05-16 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|